Evidence map›Paper›PMID 41113345›Full record

ArticleInternational journal of pharmaceutics: X2025

Co-assembling de novo designed peptide with high-payload drug protein for noninvasive treatment of corneal neovascularization.

Yuhua Tong, Sijie Zhou, Yongjie Guo, Xiaoli Jin, Meiting Yu, Chunyun Feng, Hao Chen, Xingjie Zan, Jinyang Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of pharmaceutics: X, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yuhua TongDepartment of Ophthalmology, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, Quzhou, 324000 Zhejiang, China.
Sijie ZhouNational Clinical Research Center for Ocular Diseases, Eye Hospital, Wenzhou Medical University, Wenzhou 325027, China.
Yongjie GuoNo. 906 Hospital of People's Liberation Army, Wenzhou 325000, Zhejiang, China.
Xiaoli JinNational Clinical Research Center for Ocular Diseases, Eye Hospital, Wenzhou Medical University, Wenzhou 325027, China.
Meiting YuDepartment of Ophthalmology, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, Quzhou, 324000 Zhejiang, China.
Chunyun FengDepartment of Ophthalmology, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, Quzhou, 324000 Zhejiang, China.
Hao ChenNational Clinical Research Center for Ocular Diseases, Eye Hospital, Wenzhou Medical University, Wenzhou 325027, China.
Xingjie ZanWenzhou Institute, University of Chinese Academy of Sciences, Wenzhou 325000, Zhejiang, China.
Jinyang LiNational Clinical Research Center for Ocular Diseases, Eye Hospital, Wenzhou Medical University, Wenzhou 325027, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The specificity and low toxicity of protein drugs are significant for disease treatment but are strongly limited by their weak tissue penetrative capacity. Although formulating proteins with nanoparticle is an alternative strategy, the low encapsulation efficiency (EE) and loading capacity (LC) of protein drugs and their potential for protein inactivation remain significant challenges. Herein, the de novo designed peptide (Arg-His-Cys-Arg-His-Cys-Arg-His-Cys) (RHC)

Indexed as

Corneal neovascularizationNanomedicinePeptide assemblyProtein deliveryProtein drug

Identifiers

PMID41113345
PMCPMC12528919

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.